Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Angiogenesis. 2019 Jan 14;22(3):369–382. doi: 10.1007/s10456-019-09662-4

Fig. 8.

Fig. 8.

Ligand-guided targeted anti-angiogenic therapy. VEGF regulates both diseased and healthy vessels, whereas Scg3 binds only to diseased but not normal vasculatures. Anti-VEGF drugs blocks pathological and physiological angiogenesis. In contrast, anti-Scg3 mAb selectively inhibits pathological but not physiological angiogenesis.